Nalbuphine ER: Completed Phase II/III enrollment

Trevi completed enrollment of about 360 patients in a double-blind, placebo-controlled, international Phase II/III trial evaluating 60 and 120 mg oral Nalbuphine ER twice daily for 6 weeks. The trial ...